GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Shiller PE Ratio

Horizon Therapeutics (Horizon Therapeutics) Shiller PE Ratio : (As of May. 11, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Horizon Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Horizon Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Shiller PE Ratio Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Horizon Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Shiller PE Ratio falls into.



Horizon Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Horizon Therapeutics's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Horizon Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.54/119.6113*119.6113
=0.540

Current CPI (Jun. 2023) = 119.6113.

Horizon Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.080 100.274 -0.095
201312 -1.610 99.875 -1.928
201403 -3.070 100.573 -3.651
201406 -0.380 100.773 -0.451
201409 0.020 100.474 0.024
201412 -0.270 99.576 -0.324
201503 -0.160 99.975 -0.191
201506 0.200 100.573 0.238
201509 0.020 100.274 0.024
201512 0.150 99.676 0.180
201603 -0.280 99.676 -0.336
201606 0.090 101.072 0.107
201609 -0.040 100.274 -0.048
201612 -0.810 99.676 -0.972
201703 -0.560 100.374 -0.667
201706 -1.290 100.673 -1.533
201709 -0.390 100.474 -0.464
201712 -0.280 100.075 -0.335
201803 -0.900 100.573 -1.070
201806 -0.150 101.072 -0.178
201809 0.190 101.371 0.224
201812 0.500 100.773 0.593
201903 -0.190 101.670 -0.224
201906 -0.030 102.168 -0.035
201909 0.090 102.268 0.105
201912 2.840 102.068 3.328
202003 -0.070 102.367 -0.082
202006 -0.420 101.769 -0.494
202009 1.310 101.072 1.550
202012 0.820 101.072 0.970
202103 -0.550 102.367 -0.643
202106 0.670 103.364 0.775
202109 1.380 104.859 1.574
202112 0.730 106.653 0.819
202203 0.870 109.245 0.953
202206 0.260 112.734 0.276
202209 0.580 113.431 0.612
202212 0.520 115.425 0.539
202303 0.230 117.618 0.234
202306 0.540 119.611 0.540

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Horizon Therapeutics  (NAS:HZNP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Horizon Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (Horizon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Executives
Andy Pasternak officer: EVP and Chief Business Officer C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox officer: EVP, Chief Financial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman officer: EVP & Chief Medical Officer C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny officer: Chief Accounting Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton officer: EVP, General Counsel C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z. officer: EVP, Research & Development C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director, officer: President, Chairman and CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi officer: Chief Commercial Officer C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher officer: EVP Finance 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin officer: EVP, Technical Operations C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze officer: EVP, Corporate Dev't. C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler officer: EVP, General Counsel C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel director TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000